(Alliance News) - Syncona Ltd on Tuesday noted half-year results of its investees, Freeline Therapeutics Holdings PLC and Achilles Therapeutics PLC.
Syncona is a London-based investor in healthcare companies.
Freeline's interim pre-tax loss to June 30 narrowed to USD51.0 million from USD74.8 million a year ago.
Research & development costs narrowed to USD38.8 million from USD48.1 million. General and administrative expenses fell to USD16.3 million from USD24.6 million.
Freeline expects to update on three phase 1/2 trials on three diseases in the second half of 2022. Those include a dose-finding trial of FLT190 in Fabry disease, a dose-finding trial of FLT201 in Gaucher disease and efficacy data from a dose-confirmation trial of FLT180a in haemophilia B. The firm aims to release efficacy data on its Gaucher disease trial in the first half of 2023.
Meanwhile, Achilles' interim pretax loss to June 30 widened to USD34.6 million from USD29.9 million the prior year.
Research & development costs increased to USD27.8 million from USD19.7 million.
Achilles expects to provide initial data on a Phase 1/2a trial of its T cell therapy in non-small cell lung cancer and melanoma in the fourth quarter of 2022.
Syncona added that Achilles' cash balance of USD202 million is able "to support all planned operations into the second quarter of 2025, including completion of its ongoing Phase 1/2a clinical trials".
Syncona shares were flat at 207.50 pence each in London on Tuesday afternoon.
By Tom Budszus; tombudszus@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
Syncona (SYNC)